Secondary Metabolites from Marine-Derived Fungi from China

Liu, Zhen; Frank, Mary Margaret; Yu, Xiaoqin; Yu, Haiqian; Tran-Cong, Nam Michael; Gao, Ying; Proksch, Peter

doi:10.1007/978-3-030-37865-3_2

Cited by 17 publications

(12 citation statements)

References 179 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the discovery of new natural products from terrestrial sources is shrinking, large quantities of MNPs have been reported, especially those from marine microorganisms. The extreme marine environment, including high salinity, intensely high pressure, absence of sun light, and deficiency of nutrients, endows marine microorganisms with unique biodiversity and metabolic pathways, leading to the production of structurally unique and biologically diverse MNPs [ 2 ]. Recently, the upward trend in the discovery of new MNPs from marine microorganisms continues unabated.…”

Section: Introductionmentioning

confidence: 99%

New Drimane Sesquiterpenes and Polyketides from Marine-Derived Fungus Penicillium sp. TW58-16 and Their Anti-Inflammatory and α-Glucosidase Inhibitory Effects

Gou¹,

Tian²,

Wei

et al. 2021

Marine Drugs

View full text Add to dashboard Cite

Marine fungi-derived natural products represent an excellent reservoir for the discovery of novel lead compounds with biological activities. Here, we report the identification of two new drimane sesquiterpenes (1 and 2) and six new polyketides (3–8), together with 10 known compounds (9–18), from a marine-derived fungus Penicillium sp. TW58-16. The planar structures of these compounds were elucidated by extensive 1D and 2D NMR, which was supported by HR-ESI-MS data. The absolute configurations of these compounds were determined by experimental and calculated electronic circular dichroism (ECD), and their optical rotations compared with those reported. Evaluation of the anti-inflammatory activity of compounds 1–18 revealed that compound 5 significantly inhibited the release of nitric oxide (NO) induced by lipopolysaccharide (LPS) in RAW264.7 cells, correlating with the inhibition of expression of inducible nitric oxide synthase (iNOS). In addition, we revealed that compounds 1, 3–6, 14, 16, and 18 showed strong α-glucosidase inhibitory effects with inhibition rates of 35.4%, 73.2%, 55.6%, 74.4%, 32.0%, 36.9%, 88.0%, and 91.1%, respectively, which were comparable with or even better than that of the positive control, acarbose. Together, our results illustrate the potential of discovering new marine-based therapeutic agents against inflammation and diabetes mellitus.

show abstract

Section: Introductionmentioning

confidence: 99%

New Drimane Sesquiterpenes and Polyketides from Marine-Derived Fungus Penicillium sp. TW58-16 and Their Anti-Inflammatory and α-Glucosidase Inhibitory Effects

Gou¹,

Tian²,

Wei

et al. 2021

Marine Drugs

View full text Add to dashboard Cite

show abstract

“…Previously, bioactive polyketides were identified from Phomopsis sp. isolated from both marine and terrestrial habitats [ 13 , 59 , 60 ]. Microdochium sp.…”

Section: Discussionmentioning

confidence: 99%

“…The potential of marine fungi in biomedicine is diverse. Several marine fungal species have been shown to inhibit cancer cell growth [12][13][14]. The enormous potential of marine fungi to produce antibiotic compounds was reviewed recently [15,16].…”

Section: Introductionmentioning

confidence: 99%

Marine fungi showing multifunctional activity against human pathogenic microbes and cancer

2022

View full text Add to dashboard Cite

Multifunctional drugs have shown great promise in biomedicine. Organisms with antimicrobial and anticancer activity in combination with antioxidant activity need further research. The Red Sea and the Arabian Gulf coasts were randomly sampled to find fungi with multifunctional activity. One hundred strains (98 fungi and 2 lichenized forms) were isolated from 15 locations. One-third of the isolates inhibited clinical bacterial (Staphylococcus aureus, Bacillus subtilis, Vibrio cholerae, Salmonella typhi, S. paratyphi) and fungal pathogens (Talaromycets marneffei, Malassezia globose, Cryptococcus neoformans, Candida albicans, Aspergillus fumigatus) and four cancer cell lines (Hep G2 liver, A-549 lung, A-431skin, MCF 7 breast cancer). Bacterial and cancer inhibition was often accompanied by a high antioxidant activity, as indicated by the principal component analysis (PCA). PCA also indicated that fungal and bacterial pathogens appeared to be inhibited mostly by different marine fungal isolates. Strains with multifunctional activity were found more from the Rea Sea than from the Arabian Gulf coasts. The highest potential for multifunctional drugs were observed for Acremonium sp., Acrocalymma sp., Acrocalymma africana, Acrocalymma medicaginis (activity reported for the first time), Aspergillus sp. Cladosporium oxysporum, Emericellopsis alkaline, Microdochium sp., and Phomopsis glabrae. Lung, skin, and breast cancers were inhibited 85%–97% by Acremonium sp, while most of the isolates showed low inhibition (ca 20%). The highest antifungal activity was observed for Acremonium sp., Diaporthe hubeiensis, Lasiodiplodia theobromae, and Nannizia gypsea. One Acremonium sp. is of particular interest to offer a multifunctional drug; it displayed both antifungal and antibacterial activity combined with high antioxidant activity (DPPH scavenging 97%). A. medicaginis displayed combined antibacterial, anticancer, and antioxidant activity being of high interest. Several genera and some species included strains with both high and low biological activities pointing out the need to study several isolates to find the most efficient strains for biomedical applications.

show abstract

“…The major fungal producers of the natural products are recognized to be marine fungi of genera Aspergillus -28%, and Penicillum -11%. (Liu et al, 2020;Fadia et al, 2021;Youssef et al, 2021). Secondary metabolites of marine fungi include peptides, alkaloids, terpenoids, steroids, lactones, polyketides (Alves et al, 2019;Ogaki et al, 2020;El-Kashef et al, 2021).…”

Section: Marine Organisms Producing Cytotoxic Compoundsmentioning

confidence: 99%

Anti-tumour drugs of marine origin currently at various stages of clinical trials (review)

Bocharova

Копытина

Slynko

2021

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

Oncological diseases for a long time have remained one of the most significant health problems of modern society, which causes great losses in its labour and vital potential. Contemporary oncology still faces unsolved issues as insufficient efficacy of treatment of progressing and metastatic cancer, chemoresistance, and side-effects of the traditional therapy which lead to disabilities among or death of a high number of patients. Development of new anti-tumour preparations with a broad range of pharmaceutical properties and low toxicity is becoming increasingly relevant every year. The objective of the study was to provide a review of the recent data about anti-tumour preparations of marine origin currently being at various phases of clinical trials in order to present the biological value of marine organisms – producers of cytotoxic compounds, and the perspectives of their use in modern biomedical technologies. Unlike the synthetic oncological preparations, natural compounds are safer, have broader range of cytotoxic activity, can inhibit the processes of tumour development and metastasis, and at the same time have effects on several etiopathogenic links of carcinogenesis. Currently, practical oncology uses 12 anti-tumour preparations of marine origin (Fludarabine, Cytarabine, Midostaurin, Nelarabine, Eribulin mesylate, Brentuximab vedotin, Trabectedin, Plitidepsin, Enfortumab vedotin, Polatuzumab vedotin, Belantamab mafodotin, Lurbinectedin), 27 substances are at different stages of clinical trials. Contemporary approaches to the treatment of oncological diseases are based on targeted methods such as immune and genetic therapies, antibody-drug conjugates, nanoparticles of biopolymers, and metals. All those methods employ bioactive compounds of marine origin. Numerous literature data from recent years indicate heightened attention to the marine pharmacology and the high potential of marine organisms for the biomedicinal and pharmaceutic industries.

show abstract

Secondary Metabolites from Marine-Derived Fungi from China

Cited by 17 publications

References 179 publications

New Drimane Sesquiterpenes and Polyketides from Marine-Derived Fungus Penicillium sp. TW58-16 and Their Anti-Inflammatory and α-Glucosidase Inhibitory Effects

New Drimane Sesquiterpenes and Polyketides from Marine-Derived Fungus Penicillium sp. TW58-16 and Their Anti-Inflammatory and α-Glucosidase Inhibitory Effects

Marine fungi showing multifunctional activity against human pathogenic microbes and cancer

Anti-tumour drugs of marine origin currently at various stages of clinical trials (review)

Contact Info

Product

Resources

About